Press Releases

– Nelitolimod, a class C TLR-9 agonist formerly called SD-101, is the Company’s therapeutic candidate designed to overcome biologic barriers in liver and pancreatic tumors – Nelitolimod is currently being evaluated in three Phase 1/1b studies in adults with liver and pancreatic cancers in
March 7, 2024
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, treatment refractory, and higher disease burden patients, further validating previous data in the
February 29, 2024

Subscribe to Email Alerts

Get news delivered directly to your in box